Between April 1982 and February 1997 39 patients (24 male, 15 female) with refractory acute leukemia and a median age of 31 years (19-51 years) received allogeneic marrow grafts from an HLA-identical sibling (n = 27), HLA-identical unrelated donor (MUD; n = 10) or 1-antigen mismatched unrelated donor (n = 2). Twentyeight patients had acute myelogenous leukemia and 11 acute lymphoblastic leukemia. For conditioning most patients received total body irradiation combined with cyclophosphamide (n = 23) or etoposide (n = 7). For graft-versus-host disease prophylaxis patients received cyclosporin A (CsA) and methotrexate (MTX) (n = 20), MTX alone (n = 3), CsA and methylprednisone (n = 6), or CsA alone (n = 10), respectively. As of June 1997 probability of leukemia-free survival projected to 3 years after BMT was 14% for patients given sibling marrow grafts and 28% after MUD transplantation. Transplant-related mortality projected to 3 years was 32% after sibling and 37% after MUD marrow grafting. Although not significantly different, probability of relapse projected to 3 years after BMT was lower after MUD at 56% compared to 78% with sibling BMT. Thus, high-dose chemo/radiotherapy followed by allogeneic marrow infusion has a curative potential for patients with refractory leukemia and offers the chance of long-term disease-free survival for some patients. Keywords: poor risk acute leukemia; sibling and unrelated marrow transplantation With current chemotherapies 80% of patients with acute myelogenous leukemia (AML) and more than 80% of patients with acute lymphoblastic leukemia (ALL) below the age of 50 years achieve complete hematological remission (CR).
With current chemotherapies 80% of patients with acute myelogenous leukemia (AML) and more than 80% of patients with acute lymphoblastic leukemia (ALL) below the age of 50 years achieve complete hematological remission (CR). 1, 2 Patients who are refractory to induction chemotherapy or relapse early have a poor prognosis with death due to disease or complications of therapy within a period of weeks to months. 3 Even when remissions are achieved with aggressive salvage regimens, they tend to be short-lived. 3 High-dose chemoradiotherapy followed by allogeneic marrow infusion has been used to overcome resistance of the refractory leukemic clone and has resulted in long-term survival of some patients. [4] [5] [6] Unfortunately, less than 30% of eligible patients have a suitable related donor. Bone marrow transplantation (BMT) from a human leukocyte antigen (HLA) compatible unrelated donor (MUD) has become a feasible and effective treatment for patients who could benefit from BMT but who lack an HLA-matched sibling. [7] [8] [9] Here, we present our experience in patients with primary refractory and refractory relapse of acute leukemia and compare leukemia-free survival and transplant-related mortality in patients given marrow grafts from sibling or unrelated donors.
Patients and methods

Patients
Between April 1982 and February 1997 39 consecutive patients with refractory acute leukemia, 24 males and 15 females, aged 19-51 years (median 31 years), underwent allogeneic marrow transplantation. These patients had either never achieved a complete remission (n = 17) or had relapsed and were unable to attain CR despite induction chemotherapy (n = 22). Their pre-transplant characteristics are shown in Table 1 . The conditioning regimens used for transplantation and protocols for GVHD prophylaxis were those used at our institution during the time period patients were transplanted. All patients received one to two doses of methotrexate (12 mg) intrathecally as part of the conditioning regimen.
Marrow donors were HLA-identical siblings in 27 patients, HLA-identical unrelated donors in 10 patients, and 1-antigen mismatched unrelated donors in two patients. In 25 patients ABO incompatibility and in 14 patients a sex No. = number; AML = acute myelogenous leukemia; ALL = acute lymphoblastic leukemia; CNS = central nervous system; BM = bone marrow; BMT = bone marrow transplantation; dg = diagnosis; CY = cyclophosphamide; s = single; f = fractionated; TBI = total body irradiation; BU = busulfan; VP16 = etoposide; A = cytosine arabinoside; GVHD = graft-versus-host disease; CsA = cyclosporin A; MTX = methotrexate; Pred = prednisone; Serol = serologic; MLC = mixed lymphocyte culture; LBT = ligation-based typing.
mismatch between donor and recipient were present. Bone marrow was harvested and infused as previously described. 10 The total number of nucleated marrow cells infused ranged from 0.95 to 5. 11 three patients MTX alone, six patients CsA and methylprednisone, 12 and 10 patients CsA only.
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The clinical diagnosis of GVHD was confirmed by appropriate biopsies and clinically graded as 0 to IV by the criteria reported for acute GVHD, and as 'none', 'limited' or 'extensive' for chronic GVHD. 10, 13 Patients were hospitalized in isolation rooms with lami-nar air-flow or reverse isolation. They received antimicrobial prophylaxis with nonabsorbable antibiotics and Pneumocystis carinii prophylaxis with cotrimoxazole. For cytomegalovirus (CMV) prophylaxis 20 patients were given CMV hyperimmunoglobulin and 22 patients acyclovir as described. 14 Packed red blood cells (RBC) were given to maintain hemoglobin concentrations above 8.0 g/dl and platelet transfusions to keep the platelet count above 20 ϫ 10 9 /l. All patients received CMV-negative blood products. Eight of 11 patients with ALL received G-CSF starting on day 1 after marrow infusion until neutrophil recovery. In AML patients no cytokines were given. Informed consent was obtained from all patients or their guardians. Data were analyzed as of 30 June 1997.
Documentation of hematopoietic engraftment
All patients had peripheral blood (PB) and reticulocyte counts on a daily basis starting 7 days before BMT until hematopoietic engraftment. Hemograms were obtained with the Sysmex NE-1000 (Toa Electronic Company, Hamburg, Germany) and white blood cell differential counting was carried out from smears after modified Wright staining. Absolute neutrophil counts (ANC) were calculated from leukocyte and differential counts. Bone marrow (BM) aspirates were performed on days 28, 100 and 365 after transplantation. Engraftment was defined as ANC of 0.5 ϫ 10 9 /l, platelets of 30 ϫ 10 9 /l and independence of RBC transfusions. Engraftment of donor cells was also documented by cytogenetic analyses (karyotype with banding) of recipient marrow cells before and after transplantation and amplification of the variable number of tandem repeats (VNTR) region within intron 40 of the von Willebrand factor gene by polymerase chain reaction (PCR) as described. 15 Chromosomal abnormalities are described according to the International System for Human Cytogenetic Nomenclature. 16 Patients were called primary refractory when they were unable to achieve first complete remission after at least two cycles of induction chemotherapy. Patient disease status was called refractory relapse when they had a relapse and did not achieve remission after salvage chemotherapy.
Histocompatibility studies and donor selection
Unrelated marrow donors were provided by Donor Centers associated with the Austrian Bone Marrow Donor Registry, National Marrow Donor Program, Minneapolis, USA (n = 3), Europdonor Foundation, Leiden, The Netherlands (n = 2), Swiss National Registry, Bern, Switzerland (n = 2), German National Registry, Ulm, Germany (n = 2), France Greffe de Moelle Registry, Paris, France (n = 1), Swedish National Registry, Stockholm, Sweden (n = 1) and Austrian Bone Marrow Donor Registry, Vienna, Austria (n = 1). HLA typing for all patients and donors was confirmed by the University Hospital of Vienna Department of Blood Group Serology. Histocompatibility studies for class I antigens consisted of serological typing according to a standard two-stage microtoxicity assay, 17 and antigens were assigned as defined by the World Health Organization HLA nomenclature committee effective at the time of transplantation. 18 In 21 (54%) pairs, HLA-DR typing was performed by the two-colour fluorescence cytotoxicity test. 17 To assess HLA class II identity mixed lymphocyte cultures were performed in addition. In the remaining 18 (46%) pairs, class II region compatibility was assessed by DRB1, DRB3, DRB5, DQB1 allele typing by hybridization of amplified DNA with ligation-based typing (LBT). 19 In addition, DRB1 and DQB1 alleles were analyzed by nucleotide sequencing of allele-specific amplified DNA. 19 
Statistical methods
Leukemia-free survival, incidence of transplant-related mortality, GVHD and relapse rates were estimated using the method of Kaplan and Meier. Comparisons were based on the generalized Wilcoxon test and the log-rank test.
Results
Engraftment
One patient (2.5%) died within 4 weeks of marrow grafting and thus was not evaluated for engraftment. Two patients had myeloid engraftment but experienced red blood cell aplasia most probably due to ABO incompatibility with the marrow donor. One patient with persistent leukemia in BM on day 28 had rapid myeloid engraftment but remained transfusion dependent. All other patients had restoration of normal hematopoiesis as indicated by rising blood cell counts and return of marrow cellularity within 4 weeks of marrow grafting. The median time for the absolute neutrophil counts to reach more than 0.5 ϫ 10 9 /l was 18 (range, 10-37) days after sibling and 22 (range, 15-29) days after MUD marrow grafting, respectively. Platelet counts above 30 ϫ 10 9 /l and hematocrit values above 30% without the need for further transfusions were reached after a median of 31 (range, 10-154) and 25 (range, 10-118) days after related BMT and 25 (range, 13-35) and 23 (range, 11-38) days after MUD transplantation, respectively.
Marrow biopsies on days 28 and 100 showed trilineage engraftment in the surviving patients. Marrow obtained after grafting was of donor origin, as documented by the exclusive presence of cells with donor karyotype on cytogenetic analysis of 14 patients, and donor ABO blood groups in 15 patients. In 19 patients, peripheral blood cells were analyzed after marrow grafting by VNTR-PCR revealing donor genotype in all patients.
Transplant-related mortality (TRM)
Eleven patients (28%) died of transplant complications: five of bacterial infections, three of fungal infections, one of CMV infection, one of interstitial pneumonitis and one of severe veno-occlusive disease (VOD) of the liver. In five patients infections were associated with severe acute GVHD and in two patients with severe VOD. In patients given sibling marrow grafts Kaplan and Meier analyses revealed a probability of TRM projected to 3 years of 32% compared to 37% after unrelated BMT (Figure 1) . No sig- nificant correlation between age, disease status, conditioning regimen used and incidence of TRM was seen.
GVHD
Of the 38 patients with sustained engraftment, 29 developed acute GVHD grades I-IV (76%) consisting of grades III-IV in 11 patients (29%). In univariant analysis no significant correlation between age at transplantation, conditioning regimen used, GVHD prophylaxis or donor sex and incidence of acute GVHD was seen. Due to small patient numbers no multivariant analysis was performed. The probability of developing grades I-IV acute GVHD was 74% after sibling and 75% after MUD transplantation. The probability of developing grades II-IV acute GVHD was 44% in sibling marrow recipients and 66% in MUD transplants. These differences were statistically insignificant. Thirty-one patients survived longer than 80 days; three developed extensive chronic GVHD (10%) and another eight limited chronic GVHD (26%). Of the three patients with extensive chronic GVHD, one died from CMV infection, one died from relapse and in one chronic GVHD resolved with CsA and steroids. The probability of developing limited or extensive chronic GVHD was 18% and 7% after sibling and 25% and 8% after MUD transplantation. Probability of survival was better in patients experiencing limited chronic GVHD compared to patients without cGVHD.
Relapse
One patient died of transplant-related complications within 4 weeks of unrelated BMT and her remission status could not be ascertained. Complete hematological remission was achieved in 36 of 38 evaluable patients (95%). Two patients had persistent leukemia in the marrow seen either morphologically on day 28 (n = 1) or by polymerase chain reaction analyses with consistent BCR-ABL positivity in a patient with ALL. The latter progressed to overt leukemia 3 months after BMT. Eighteen patients (47%) experienced leukemic relapse with a median onset at 7 (range, 1-38) months after BMT. The probability of relapse after sibling and MUD marrow grafting was 78% and 56%, but insig- nificantly different (Figure 2 ). Primary disease, disease status at BMT, percentage of blasts in BM at BMT, and conditioning regimen did not significantly influence relapse incidence. However, patients with grades I-IV acute GVHD had a significantly lower probability of relapse than patients without GVHD (P = 0.01).
Twelve of 15 patients with prior chromosomal abnormalities had normal marrow karyotypes after BMT. In the 20 patients experiencing relapse or persistent disease after marrow grafting cytogenetic analyses at BMT were either normal (n = 5), not done (n = 5), or had good (n = 1) or poor (n = 9) prognostic features.
Leukemia-free survival
As of 30 June 1997 eight of 39 patients (21%) remain alive and disease-free with a median follow-up of 4.5 years (range, 0.5-11 years). Among the eight long-term leukemia-free survivors five were primary refractory and three had a refractory relapse at BMT. Five of the eight patients (62%) have a Karnofsky score of 100%, and three (38%) between 90% and 95%. One patient requires treatment for chronic GVHD. Probability of LFS at 3 years after BMT was 14% for patients given sibling marrow grafts and 28% after MUD transplantation (Figure 3) . This difference, how- ever, is not statistically significant. No significant difference in LFS between patients older or younger than 30 years at BMT or patients with AML or ALL was observed. Probability of LFS projected to 3 years after BMT is 14% for patients transplanted with refractory relapse and 24% for patients with primary refractory disease.
Discussion
This study confirms previous findings that transplantation of hematopoietic stem cells from an HLA-compatible sibling or unrelated donor can result in long-term leukemiafree survival in patients with otherwise incurable acute leukemia. [4] [5] [6] [7] [8] [9] [20] [21] [22] [23] All patients were either refractory to induction chemotherapy or had relapsed and had no complete response to salvage therapy. Eight of 39 patients (21%) with poor prognostic features are alive and leukemia-free after a median observation time of 4.5 years after BMT. Our results obtained in HLA-identical sibling marrow transplantation compare favorably with reported leukemia-free survival rates of 12-20%. [4] [5] [6] The series is too small to allow any conclusions to be drawn about prognostic factors with BMT for resistant disease. The IBMTR report, however, found that age over 30 years, poor performance status at transplant, active infection at the time of transplant, extensive prior therapy and a higher number of blasts in the BM at the time of transplant are adverse risk factors. 4 With a probability of 28% at 3 years a trend towards improved leukemia-free survival was observed in our patients given marrow from MUD compared to sibling donors. Although not statistically significant, these results in patients with poor-risk acute leukemia are promising and compare favorably with previously reported LFS rates of 10-32% in unrelated BMT. [7] [8] [9] [20] [21] [22] [23] The main cause of death in our patients was recurrent leukemia. Sixteen of 27 patients (59%) given sibling marrow grafts died from relapse compared to seven deaths (26%) due to transplant-related causes. In our patients given MUD marrow grafts, four patients (33%) died from transplant-related complications and four from leukemic relapse, respectively. Although, statistically insignificant, a lower probability of relapse was observed with MUD than sibling marrow transplants. Patients with acute GVHD had significantly lower relapse rates than patients without acute GVHD. Furthermore, the majority of our patients experiencing relapse after sibling or MUD transplantation had cytogenetic abnormalities known to have an adverse impact on response rate and CR duration in acute leukemia. 24, 25 Our results confirm previous findings of higher rates of acute GVHD in MUD transplants compared to sibling BMT. 8, 9, 20, 22 The level of donor/recipient disparity did not affect the probability of developing acute GVHD in our series. However, only two pairs with a mismatch in the HLA-A or HLA-C region were included. One of these patients experienced relapse on day 77 after BMT and the other died of grade IV acute GVHD. The higher rates of acute and chronic GVHD in MUD transplantation predispose to opportunistic infections and contribute to higher mortality rates. In our series the incidence of transplantrelated mortality was lower than reported previously in comparable patients with up to 62% of TRM. 20, 21 Unlike other studies no failure to engraft was observed in our patients given MUD marrow grafts. 7, 8, 21, 23 The probability of graft failure is known to correlate with the degree of HLA incompatibility and the use of T cell depletion. 23, 26 Furthermore, infusion of a higher marrow cell dose was associated with a lower incidence of graft failure and faster hematopoietic engraftment. 27, 28 Sierra et al 20 recently reported faster hematopoietic engraftment and lower rates of lethal bacterial or fungal infections in patients receiving MUD transplants in remission with higher marrow cell doses. Due to small patient numbers no correlation between infused marrow cell dose and transplant-related complications could be discerned in our patients.
In summary, marrow transplantation from HLA-identical sibling or MUD has proven feasible and effective for treatment of patients with refractory or relapsed acute leukemia. The lower risk of relapse appears to be an advantage after unrelated BMT resulting in improved leukemia-free survival compared to sibling marrow grafting. However, patients with poor prognostic cytogenetic abnormalities remain at high risk of relapse and benefit from high-dose therapies seems questionable.
